RANCHO CORDOVA, Calif.,
Sept. 13 /PRNewswire/ --
ThermoGenesis Corp. (Nasdaq: KOOLD), a leading supplier of
innovative products and services that process and store adult stem
cells, said today that it has been informed by NASDAQ that the
Company is in compliance with all NASDAQ listing standards,
including the minimum price bid requirement.
"We are pleased to have retained our presence on the NASDAQ
market," said J. Melville Engle,
Chief Executive Officer of ThermoGenesis. "We finished fiscal 2010
in strong fashion and are off to a solid start in fiscal 2011 as we
execute on our strategies to drive shareholder value," he
added.
About ThermoGenesis Corp.
ThermoGenesis Corp. (www.thermogenesis.com) is a leader in
developing and manufacturing automated blood processing systems and
disposable products that enable the manufacture, preservation and
delivery of cell and tissue therapy products. These include:
- The BioArchive® System, an automated cryogenic device, is used
by cord blood stem cell banks in more than 30 countries for
cryopreserving and archiving cord blood stem cell units for
transplant.
- AXP® AutoXpress™ Platform (AXP), a proprietary family of
automated devices that includes the AXP and the MXP™ MarrowXpress™
and companion sterile blood processing disposables for harvesting
stem cells in closed systems. The AXP device is used for the
processing of cord blood. The MXP is used for the preparation of
cell concentrates, including stem cells, from bone marrow aspirates
in the laboratory setting.
- The Res-Q™ 60 BMC (Res-Q), a point-of-care system that is
designed for the preparation of cell concentrates, including stem
cells, from bone marrow aspirates.
- The CryoSeal® FS System, an automated device and companion
sterile blood processing disposable, is used to prepare fibrin
sealants from plasma in about an hour. The CryoSeal FS System is
approved in the U.S. for liver resection surgeries. The CryoSeal FS
System has received the CE-Mark which allows sales of the product
throughout the European community.
This press release contains forward-looking statements, and such
statements are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
involve risks and uncertainties that could cause actual outcomes to
differ materially from those contemplated by the forward-looking
statements. Several factors, including timing of FDA approvals,
changes in customer forecasts, our failure to meet customers'
purchase order and quality requirements, supply shortages,
production delays, changes in the markets for customers' products,
introduction timing and acceptance of our new products scheduled
for fiscal years 2010 and 2011, and introduction of competitive
products and other factors beyond our control, could result in a
materially different revenue outcome and/or in our failure to
achieve the revenue levels we expect for fiscal 2010 and 2011.
A more complete description of these and other risks that
could cause actual events to differ from the outcomes predicted by
our forward-looking statements is set forth under the caption "Risk
Factors" in our annual report on Form 10-K and other reports we
file with the Securities and Exchange Commission from time to time,
and you should consider each of those factors when evaluating the
forward-looking statements.
ThermoGenesis Corp.
|
|
Web site:
http://www.thermogenesis.com
|
|
Contact: Investor
Relations
|
|
+1-916-858-5107, or
|
|
ir@thermogenesis.com
|
|
|
SOURCE ThermoGenesis Corp.
Copyright . 13 PR Newswire